top of page
FDA-approved therapies for mucus symptoms in NCFBE
People living with NCFBE in the US
ARINA·1 may significantly improve the quality of life and long-term outcomes of people with NCFBE by thinning mucus and enabling its clearance out of the lungs, as well as acting as a potent anti-inflammatory agent within the airway.
Non-cystic fibrosis bronchiectasis (NCFBE) is a disease characterized by dilated airways with mild to moderate airway obstruction and impaired mucociliary clearance that leads to a complex interplay of mucus accumulation and chronic neutrophil-predominant airway inflammation and damage. Typically, people with NCFBE suffer from chronic cough, sputum production, and frequent and recurring pulmonary infections, all of which lead to decreased quality of life, clinical decline, and premature death. To date, there are no FDA-approved therapies for mucus relief for people with NCFBE.
Phase 2 Clinical Trial
Safety and efficacy of ARINA-1 in mild-to-moderate NCFBE
Quality of life, impact of ARINA·1 on mucus rheology, airway and systemic inflammatory markers
28 days on therapy; 28 days off therapy.
Patient Enrollment Status:
Other Target Indications for ARINA·1
bottom of page